Van Hise, Nicholas W.
Petrak, Russell M.
Shah, Kairav
Diaz, Melina
Chundi, Vishnu
Redell, Mark
Funding for this research was provided by:
Melinta Therapeutics
Article History
Received: 15 December 2023
Accepted: 16 January 2024
First Online: 29 February 2024
Declarations
:
: Nicholas Van Hise has served on Advisory boards and been a consultant for AbbVie, Allergan, and Melinta Therapeutics. Kairav Shah has been a consultant for Melinta Therapeutics. Mark Redell is an employee of Melinta Therapeutics. Russell Petrak, Melina Diaz and Vishnu Chundi have no conflicts of interest to report.
: Western Institutional Review Board (WIRB) was utilized as the central institutional review board for all study locations. The retrospective study was approved for analysis and publication by WIRB and patient consent was waived. Patients were treated between October 2020 and January 2022.